Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

Immunotherapeutic approaches targeting prostate cancer and its microenvironment The high frequency of prostate cancer in the population of the industrial nations and the lack of curative therapies for advanced hormone refractory disease mandates the investigation of novel, more efficient therapeutic approaches. Recent advances in rodent models have evidenced the therapeutic effects of antiprostate cancer vaccines, T cell transfer strategies and blockade of the negative regulator of T cell activation CTLA-4. Besides, several immunotherapeutic products have already been investigated in later-phase clinical trials and shown clinical benefit while maintaining an excellent quality of life for the treated patients, in particular, when compared with chemotherapy. However, there is also evidence for a synergistic effect of conventional treatment strategies and immunological antitumor approaches. For example, thermal ablation which is applied to destroy tumor tissue may help to activate tumor-specific T cells by elevating the presentation of tumor antigens to the immune system. Based on the experimental and clinical data the role of immune-based therapies is likely to become more prominent in the future years. This review summarizes results from contemporary immunologic therapies and clinical trials against prostate cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

Loading next page...
 
/lp/springer-journals/immunotherapeutic-approaches-targeting-prostate-cancer-and-its-YaPmYL167D
Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag Wien
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-012-0021-4
Publisher site
See Article on Publisher Site

Abstract

The high frequency of prostate cancer in the population of the industrial nations and the lack of curative therapies for advanced hormone refractory disease mandates the investigation of novel, more efficient therapeutic approaches. Recent advances in rodent models have evidenced the therapeutic effects of antiprostate cancer vaccines, T cell transfer strategies and blockade of the negative regulator of T cell activation CTLA-4. Besides, several immunotherapeutic products have already been investigated in later-phase clinical trials and shown clinical benefit while maintaining an excellent quality of life for the treated patients, in particular, when compared with chemotherapy. However, there is also evidence for a synergistic effect of conventional treatment strategies and immunological antitumor approaches. For example, thermal ablation which is applied to destroy tumor tissue may help to activate tumor-specific T cells by elevating the presentation of tumor antigens to the immune system. Based on the experimental and clinical data the role of immune-based therapies is likely to become more prominent in the future years. This review summarizes results from contemporary immunologic therapies and clinical trials against prostate cancer.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 5, 2012

References